We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-19.01%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$911M
AUM Growth
-$333M
Cap. Flow
-$41.3M
Cap. Flow %
-4.53%
Top 10 Hldgs %
87.82%
Holding
27
New
1
Increased
6
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$17.1M
2
IRON icon
Disc Medicine
IRON
+$16.3M
3
KYTX icon
Kyverna Therapeutics
KYTX
+$3.12M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.19M
5
XLO icon
Xilio Therapeutics
XLO
+$1.1M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$52.6M
2
NRIX icon
Nurix Therapeutics
NRIX
+$16.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$8.87M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$2.35M
5
ANNX icon
Annexon
ANNX
+$1.31M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$205M 22.46%
2,697,267
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.34B
$201M 22.09%
10,473,913
– –
IRON icon
3
Disc Medicine
IRON
$2.97B
$80.9M 8.89%
1,795,735
+478,522
+36% +$16.3M
DNTH icon
4
Dianthus Therapeutics
DNTH
$6.09B
$78M 8.56%
3,013,423
+21,395
+0.7% +$514K
PHVS icon
5
Pharvaris
PHVS
$2.44B
$62.1M 6.82%
3,303,381
– –
SVRA icon
6
Savara
SVRA
$1.19B
$58.7M 6.44%
14,565,457
– –
ANNX icon
7
Annexon
ANNX
$886M
$41.4M 4.55%
8,449,208
-254,060
-3% -$1.31M
KYTX icon
8
Kyverna Therapeutics
KYTX
$484M
$25.3M 2.77%
3,368,370
+204,502
+6% +$3.12M
TNGX icon
9
Tango Therapeutics
TNGX
$4.41B
$24.8M 2.72%
2,892,663
– –
SLDB icon
10
Solid Biosciences
SLDB
$900M
$22.9M 2.51%
4,034,582
– –
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$17.4M 1.91%
346,547
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$14.2M 1.56%
2,749,808
– –
IPSC icon
13
Century Therapeutics
IPSC
$361M
$13.8M 1.51%
+5,410,361
New +$17.1M
CABA icon
14
Cabaletta Bio
CABA
$455M
$12.3M 1.36%
1,649,964
+32,600
+2% +$400K
XFOR icon
15
X4 Pharmaceuticals
XFOR
$460M
$9.81M 1.08%
563,859
– –
ARQT icon
16
Arcutis Biotherapeutics
ARQT
$3.18B
$9.59M 1.05%
1,030,703
-980,984
-49% -$8.87M
AVIR icon
17
Atea Pharmaceuticals
AVIR
$420M
$8.23M 0.9%
2,485,638
– –
RPID icon
18
Rapid Micro Biosystems
RPID
$86.2M
$5.57M 0.61%
8,434,560
– –
CCCC icon
19
C4 Therapeutics
CCCC
$412M
$5.14M 0.56%
1,111,910
-30,300
-3% -$181K
NAUT icon
20
Nautilus Biotechnolgy
NAUT
$115M
$4.68M 0.51%
2,000,000
– –
XLO icon
21
Xilio Therapeutics
XLO
$60.3M
$3.59M 0.39%
270,389
+70,002
+35% +$1.1M
MRNS
22
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.65M 0.29%
2,267,680
+874,300
+63% +$2.19M
IVVD icon
23
Invivyd
IVVD
$218M
$1.98M 0.22%
1,799,595
– –
ACRS icon
24
Aclaris Therapeutics
ACRS
$869M
$1.1M 0.12%
1,000,000
-2,000,000
-67% -$2.35M
NAMSW icon
25
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$872K 0.1%
100,000
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2024 Portfolio in Review

As of Q2 2024, Bain Capital Life Sciences Investors held 27 positions worth $911M, down 27% from $1.24B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $41.3M in Q2 2024, closing 2 positions and reducing 4 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $52.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Century Therapeutics worth $13.8M.

  • Bain Capital Life Sciences Investors's largest Q2 2024 buy was Century Therapeutics: 5,410,361 shares worth $13.8M.
  • Bain Capital Life Sciences Investors added most to Disc Medicine in Q2 2024, an estimated $16.3M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $8.87M.
  • Bain Capital Life Sciences Investors fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $52.6M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $911M portfolio in Q2 2024.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q2 2024.
  • Bain Capital Life Sciences Investors's portfolio value fell 27% quarter-over-quarter to $911M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2024, filed 12 Aug 2024.